Tumor marker test kit HUBI BPHScreen

for cancersPSAfree PSA

The HUBI-BPHScreen is quantitative determination of free PSA, total PSA and f/t PSA ratio in human whole blood and shows the test resuit in quantitative base along with HUBI-QUANpro . HUBI-BPHScreen is effective for prostate cancer diagnosis. Prostate Specific Antigen (PSA) is an intracellular glycoprotein (33KDa) synthesized only by the prostate gland. PSA, a normal constituent of prostate tissue, is also present in benign hyperplastia and malignant prostatic tissue, in metastatic prostatic carcinoma, and in prostatic fluid and séminal plasma, however, it is not detected in cancers of lung, colon, breast, rectum, pancréas, stomach or thyroid. The amount of PSA in the blood normally increases as a men’ s prostate enlarges with âge, however, normal total PSA concentration of men in âge 40’ s to 50’ s is less than 2.5ng/mL. The concentration of PSA is elevated in blood of prostate cancer patients. The prédictive value of PSA test is superior to that of either rectal examination or ultrasound alone. Since elevated levels of PSA are also seen in BPH (Benign Prostatic Hyperplasia) and other inflammation of urogenital tissues, measurement of blood PSA concentration is not recommended as a sole test for diagnosis of cancer. So the combination of PSA test of ultrasonography provides a better method of detecting prostate cancer than rectal examination or ultrasonography alone. Although PSA is an effective biomarker for early détection and monitoring in prostate cancer, it is increased in 25% of benign patients, especially 4~10ng/mL of PSA range. These make it difficult to discriminate prostate cancer or benign.